EVOLUS INC (EOLS)
Health Care · Medical aesthetics injectables · NASDAQ
A global performance beauty company specializing in injectable aesthetic products, primarily botulinum toxin (Jeuveau®) and hyaluronic acid gels (Evolysse™), for the direct-pay medical aesthetics market.
What EVOLUS INC does
Evolus is a global performance beauty company focused on the cash-pay aesthetic market, delivering injectable products to aesthetic practitioners. The company's primary commercial product is Jeuveau® (prabotulinumtoxinA-xvfs), a botulinum toxin type A formulation for temporary improvement of frown lines, and Evolysse™, a collection of injectable hyaluronic acid gels for treatment of wrinkles and folds including nasolabial folds, mid-face volume, lip fullness, and infraorbital hollow correction. Products are marketed in the United States, Canada, Europe, and Australia, with Evolysse™ Sculpt and Evolysse™ Lips pending FDA approval anticipated in 2026-2027.
Themes: Injectable botulinum toxin / neurotoxins, Injectable dermal fillers / hyaluronic acid gels, Medical aesthetics / cosmetic injectables, Cash-pay aesthetic market, Direct-to-practitioner distribution
Fundamentals
- Price$8.78 as of 2026-08-24 close
- Market cap$580M as of 2026-08-24
- 1-year return+14.3% 2025-08-22 close $7.68 → 2026-08-24 close $8.78
- P/En/a negative earnings
- Net margin-14.4% as of 2026-08-24
- Gross margin+66.1% as of 2026-08-24
- ROE-410.2% as of 2026-08-24
- Debt / equity22.00 as of 2026-08-24
- Revenue growth (YoY)+9.6% as of 2026-08-24
- Revenue CAGR (3y)+26.0% SEC XBRL
- Beta1.25 as of 2026-08-24
- Last reported earnings2026-08-05 SEC EDGAR Form 8-K (Item 2.02)
How EOLS compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitybottom 10% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRtop 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How EVOLUS INC looks technically
EVOLUS INC (EOLS) is trading 40.9% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 42 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 37, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 67, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 3 trading days ago. It is 3.5% below its 52-week high (its highest price of the past year).
Trend
9
| Distance from the 200-day | it is trading 40.9% above its 200-day average, the long-term trend line — a longer-term uptrend | +40.9% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $6.82 | $6.82 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $5.95 | $5.95 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 10 calendar days ago — the swings before that are what the structure reading is measured on | 10 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that upward direction; the labelling fails if price closes below 6.43. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a completed three-part correction. | possible upward five-wave sequence, in wave 4 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 42 trading days ago — a "golden cross", a bullish long-term signal | 42 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 40.9% above | +40.9% |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 37, with buyers in control | 36.6 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 67, neither overbought (above 70) nor oversold (below 30) | 67.0 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($5.93 to $8.69) — its "stochastic" reading is 89 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 89.1 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 15 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $8.69 | $8.69 |
|---|---|---|
| From the 52-week high | it is 3.5% below its 52-week high (its highest price of the past year) | -3.5% |
| Above the 52-week low | it is 117.4% above its 52-week low (its lowest price of the past year) | +117.4% |
| Below the 52-week high | it is 3.5% below its highest point of the past year | 3.5% |
| Since a 20-day breakout | it made a new 20-day high about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day high about 3 trading days ago | 3 sessions |
| All-time high | its highest closing price on record is $39.50 (set on 2018-06-07) | $39.50 |
| Given back of the 52-week move | over the past year its closes ranged ($3.94 to $8.60), and it has given back only a small part of its rise from last year’s low — 5% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $5.57 to $5.72. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 4.5% |
| From the all-time high | it is 78.8% below its all-time high | -78.8% |
| Nearest price level | it is trading 3.8% below a resistance level at $8.71 — a price it turned at twice since 2025-04-09, most recently on 2025-05-28. Since 2024-08-21 it has 10 such levels below the current price and 8 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +3.8% |
| All-time low | its lowest closing price on record is $2.85 (set on 2020-10-29) | $2.85 |
| Above the all-time low | it is 194.4% above its all-time low | +194.4% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 96% of the past ~6 months) | 96th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.4042 between its high and its low — about 4.8% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.4042 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $5.25 and $9.26 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $5.25 – $7.26 – $9.26 |
| Typical daily range (% of price) | its price moves about 4.8% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.8% |
| Stretch from the 200-day average | it is trading 6.0 daily ranges above its 200-day average price (40.9% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 6.0 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.63× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 2.3% since the prior reading | +2.3% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a bullish engulfing | 5 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 5 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-21 at essentially the same price it closed at the session before — no meaningful overnight gap | 0.0% |
|---|---|---|
| Open gap | it gapped 13.1% above the previous close 11 sessions ago and has not traded back through the level it left behind at 6.18 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +13.1% |
| Gap filled | a 3.6% gap down opened on 2026-07-20 has been "filled" 24 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 24 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 42.2 percentage points (the stock gained 44.5% while the market gained 2.3%) | +42.2% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 27.0 percentage points (the stock gained 30.1% while the market gained 3.1%) | +27.0% |
| vs market, 6 months | over the past 6 months this stock beat the market by 80.9 percentage points (the stock gained 92.0% while the market gained 11.1%) | +80.9% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 7.5 percentage points (the stock gained 13.0% while the market gained 20.5%) | -7.5% |
Signal agreement
2
| Bullish technical signals | 7 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 7 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 30% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 2.8% of the share price. | +30.1% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 46% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $5.73 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | +46.4% |
|---|---|---|
| Vs the average paid since it last reported | the price is 7% above the average price paid since it last reported on 2026-08-05 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $7.82 — a volume-weighted average of daily closes over 13 sessions, not a true tick-by-tick VWAP. | +7.3% |
Price levels it has turned at before
EOLS last closed at $8.39 on 2026-08-21. Since 2024-08-21 it has turned at 10 prices below its last close and 8 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $8.71 | Resistance | 3.8% above the last close | turned there twice · 2025-04-09 to 2025-05-28 |
| $7.75 | Support | 7.6% below the last close | turned there twice · 2025-09-05 to 2025-11-06 |
| $9.10 | Resistance | 8.5% above the last close | turned there twice · 2025-06-17 to 2025-07-16 |
| $7.35 | Support | 12.4% below the last close | turned there three times · 2025-10-29 to 2026-06-26 |
| $7.19 | Support | 14.3% below the last close | turned there three times · 2025-09-03 to 2026-07-08 |
| $10.61 | Resistance | 26.5% above the last close | turned there twice · 2024-12-26 to 2025-06-11 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes below $6.43.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $7.08 and $7.79 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a completed three-part correction, which fails on a close above $8.43.
This reading has stood for 1 trading day, since 2026-08-21.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Tested and reclaimed 200-day support · Broke out to a new 20-day high · in a strong, established uptrend (ADX) · Analyst price target recently RAISED · beating the market | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.43 mean, 1=Strong Buy…5=Strong Sell) — 6 analysts
- Mean price target$15.00 range $12.00 – $20.00; median $14.00
Analyst estimates, as of 2026-08-19. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for EOLS
- Consensus EPS estimate-$0.06 next reporting period, as of 2026-08-19
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Tariff exposure: Jeuveau® is manufactured and imported from South Korea; April 2026 White House proclamation authorizes tariffs on certain pharmaceutical imports from South Korea, with uncertain timing and scope, potentially impacting product costs and margins.","Consumer discretionary sensitivity: Lower consumer confidence and weakening discretionary spending due to inflation, tariffs, and economic volatility have negatively impacted aesthetic procedure demand and future sales.","Market competition: BOTOX (onabotulinumtoxinA) dominates the neurotoxin market, and the company faces competition from multiple established injectable filler manufacturers in the hyaluronic acid gel segment."]
What changed in the latest 10-Q
AI-assisted comparison of EOLS's 10-Q filed 2026-05-04 against the prior one filed 2025-11-05.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing specifies Evolysse® with registered trademark symbol (®) instead of trademark symbol (™) in multiple instances
- Newer filing adds: 'delivering breakthrough products with a customer-centric approach' language structure change
- Newer filing includes new section on tariffs, including February 20, 2026 U.S. Supreme Court invalidation of IEEPA tariffs and April 2, 2026 White House proclamation on patented pharmaceuticals imports from South Korea
- Newer filing adds specific discussion of geopolitical tensions in Middle East and their potential impact on energy markets and supply chains
- Newer filing adds discussion of variable rate debt and interest rate sensitivity as of March 31, 2026
- Newer filing includes new 'Recent Key Developments' section describing March 3, 2026 Loan and Security Agreement with Eclipse Business Capital for $30.0 million Revolving Credit Facility
- Newer filing specifies that Evolysse® Sculpt approval is anticipated in 2026 and Evolysse® Lips in 2027, rather than both in 2026 and 2027
- Newer filing changes European launch timing from 'first half of 2026' to 'second quarter of 2026'
- Newer filing removes 'portfolio bundles' from customer adoption programs mentioned in older filing
- Removed:
- Older filing references Annual Report on Form 10-K for year ended December 31, 2024; newer filing references December 31, 2025
- Older filing includes 'fluctuations in interest rates' in Market Trends section; newer filing removes this general reference
- Older filing references 'financial and credit markets' in opening sentence of Market Trends; newer filing removes this phrase
- Older filing includes '2025 Key Developments' section with specific items (Evolysse launch in April, Pharmakon A&R Loan Agreement, PMA submission, restructuring costs); newer filing replaces with 'Recent Key Developments' focused on March 2026 Eclipse facility
- Older filing includes 'Restructuring costs' line item ($1.4 million) in Results of Operations; newer filing does not include this
- Older filing comparison is for three months ended September 30, 2025 vs. 2024; newer filing comparison is for three months ended March 31, 2026 vs. 2025
- Older filing mentions service revenue of $0.9 million from Canada distribution partner in 2024; newer filing shows $0.390 million service revenue in Q1 2026
- Reworded:
- Newer filing: 'delivering breakthrough products with a customer-centric approach in the cash-pay aesthetic market' vs. older: 'with a customer-centric approach to delivering breakthrough products in the cash-pay aesthetic market'
- Newer filing: Evolysse® registered trademark (®) throughout vs. older: Evolysse™ trademark (™) throughout
- Newer filing adds 'portfolio bundles' is removed from the list of programs ('promotional events and pricing strategies' remains)
- Newer filing expands tariff discussion significantly with specific dates and geopolitical context, whereas older filing has general statement about tariffs impacting discretionary spending
- Market Trends section in newer filing reorganized with more detailed tariff and geopolitical subsections vs. older filing's single paragraph approach
- Notes:
- The two filings compare different fiscal periods (Q1 2026 vs. Q3 2025), so some differences reflect forward progression of time rather than document revisions
- Newer filing text appears truncated at 'Interest e' in the Results of Operations table, preventing full comparison of that section
- Older filing text also appears truncated at 'respectivel' at the end, preventing complete comparison of Gross Profit Margin discussion
Risk Factors
- Added:
- Statement that risks update/supersede risks in 10-K filed March 3, 2026 (newer filing reference)
- Net loss of $10.7 million for three months ended March 31, 2026
- Net losses of $51.6 million for year ended December 31, 2025
- Accumulated deficit of $671.7 million as of March 31, 2026
- Language about maintaining cost controls as part of profitability ability
- Removed:
- Reference to 10-K filed March 4, 2025 for year ended December 31, 2024
- Reference to Q2 2025 10-Q filed August 5, 2025
- Net loss of $51.8 million for nine months ended September 30, 2025
- Net loss of $61.7 million for year ended December 31, 2023
- Accumulated deficit of $661.2 million as of September 30, 2025
- Specific competitor examples: Revance Therapeutics' Daxxify approval on September 8, 2022
- Specific competitor examples: Hugel, Inc. approval on February 29, 2024
- Reference to Galderma S.A. and Medytox BLA submissions to FDA
- Discussion of Phase III clinical development competitors in North America for glabellar lines treatment
- Language about expected further increase in U.S. injectable botulinum toxin market competition
- Reference to 'consolidated' financial statements (changed to 'condensed consolidated')
- Reworded:
- Risk factor title changed from 'We have incurred significant losses since our inception.' to 'We have incurred significant losses since our inception, and we may continue to incur losses, which could adversely affect the market price of our common stock and our ability to raise additional capital.'
- Changed 'Evolysse™' (trademark symbol) to 'Evolysse ®' (registered trademark symbol) in multiple instances
- Added language 'While we strive to achieve profitability in the future, we may not be able to sustain profitability in subsequent periods' versus prior 'Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods'
- Removed 'previously disclosed in Part II, Item 1A of our Quarterly Report on Form 10-Q for the quarter ended June 30, 2025' from supersession statement
- Expanded opening risk statement with explanatory phrase about what 'seriously harmed' includes and added sentence about Company's beliefs and opinions regarding materiality
- Notes:
- The older filing text appears truncated at the end of the second risk factor (cuts off mid-sentence)
- The newer filing text also appears truncated at the end (cuts off mid-sentence)
- Comparison is limited to the portions of text provided; full sections may contain additional changes not visible in these excerpts
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days.
- Last 180 days0 buys · 4 sells ($796936) — 2 selling insiders
Most recent open-market transaction: 2026-03-20. As of 2026-08-25.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about EOLS's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding EOLS as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 6,746,408
- Reported value $27,727,740
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 2 increased, 3 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
EOLS had 5,568,442 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
EOLS had 8.43% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 8.74 days to cover at the same settlement.
- Reported short interest (shares) 5,568,442
- Short interest (% of shares outstanding) 8.43%
- Prior settlement (shares) 5,905,990
- Reported change -5.72%
- Days to cover (reported) 8.74
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- BOTOX (Allergan/AbbVie)
- Dysport (Galderma)
- Xeomin (Merz)
- Restylane (Galderma)
- Juvéderm (Allergan/AbbVie)
- Radiesse (Merz)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Frequently asked questions
What does EVOLUS INC (EOLS) do?
Evolus is a global performance beauty company focused on the cash-pay aesthetic market, delivering injectable products to aesthetic practitioners. The company's primary commercial product is Jeuveau® (prabotulinumtoxinA-xvfs), a botulinum toxin type A formulation for temporary improvement of frown lines, and Evolysse™, a collection of injectable hyaluronic acid gels for treatment of wrinkles and folds including nasolabial folds, mid-face volume, lip fullness, and infraorbital hollow correction.
What sector is EVOLUS INC (EOLS) in?
EVOLUS INC (EOLS) is classified in the Health Care sector. Its industry is Medical aesthetics injectables. It trades on NASDAQ.
Who are EVOLUS INC's (EOLS) competitors?
Notable peers of EVOLUS INC (EOLS) include BOTOX (Allergan/AbbVie), Dysport (Galderma), Xeomin (Merz), Restylane (Galderma) and Juvéderm (Allergan/AbbVie). This peer set is informational only — not financial advice.
Is EVOLUS INC (EOLS) overbought or oversold right now?
EVOLUS INC (EOLS) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 67, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on EOLS come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.